



PubMed	Nucleotide	Protein	Genome	Structure	PopSet	Taxonomy	OMIM	Books
Search	PubMed	▼	for	Godiska R	Go	Clear		
Limits		Preview/Index		History	Clipboard	Details		

Display	Summary	▼	Sort	▼	Save	Text	Clip/Add	Order
Show:	20	▼	Items 1-16 of 16				One page.	

Entrez  
PubMed

- ☐ **1:** Smith DJ, King WF, Godiska R. Related Articles, Links  
Passive transfer of immunoglobulin Y antibody to Streptococcus mutans glucan binding protein B can confer protection against experimental dental caries.  
Infect Immun. 2001 May;69(5):3135-42.  
PMID: 11292733 [PubMed - indexed for MEDLINE]

PubMed  
Services

- ☐ **2:** Worledge KL, Godiska R, Barrett TA, Kink JA. Related Articles, Links  
Oral administration of avian tumor necrosis factor antibodies effectively treats experimental colitis in rats.  
Dig Dis Sci. 2000 Dec;45(12):2298-305.  
PMID: 11258548 [PubMed - indexed for MEDLINE]

Related  
Resources

- ☐ **3:** Bochner BS, Bickel CA, Taylor ML, MacGlashan DW Jr, Gray PW, Raport CJ, Godiska R. Related Articles, Links  
Macrophage-derived chemokine induces human eosinophil chemotaxis in a CC chemokine receptor 3- and CC chemokine receptor 4-independent manner.  
J Allergy Clin Immunol. 1999 Mar;103(3 Pt 1):527-32.  
PMID: 10069890 [PubMed - indexed for MEDLINE]

- ☐ **4:** Chantry D, DeMaggio AJ, Brammer H, Raport CJ, Wood CL, Schweickart VL, Epp A, Smith A, Stine JT, Walton K, Tjoelker L, Godiska R, Gray PW. Related Articles, Links  
Profile of human macrophage transcripts: insights into macrophage biology and identification of novel chemokines.  
J Leukoc Biol. 1998 Jul;64(1):49-54. Review.  
PMID: 9665274 [PubMed - indexed for MEDLINE]

- ☐ **5:** Imai T, Chantry D, Raport CJ, Wood CL, Nishimura M, Godiska R, Yoshie O, Gray PW. Related Articles, Links  
Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4.  
J Biol Chem. 1998 Jan 16;273(3):1764-8.  
PMID: 9430724 [PubMed - indexed for MEDLINE]

- ☐ **6:** Godiska R, Chantry D, Raport CJ, Sozzani S, Allavena P, Leviten D, Mantovani A, Gray PW. Related Articles, Links  
Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells.  
J Exp Med. 1997 May 5;185(9):1595-604.  
PMID: 9151897 [PubMed - indexed for MEDLINE]

- ☐ **7:** [Hromas R, Gray PW, Chantry D, Godiska R, Krathwohl M, Fife K, Bell GI, Takeda J, Aronica S, Gordon M, Cooper S, Broxmeyer HE, Klemsz MJ.](#) Related Articles, Links  
Cloning and characterization of exodus, a novel beta-chemokine.  
Blood. 1997 May 1;89(9):3315-22.  
PMID: 9129037 [PubMed - indexed for MEDLINE]
- ☐ **8:** [Godiska R, Chantry D, Raport CJ, Schweickart VL, Trong HL, Gray PW.](#) Related Articles, Links  
Monocyte chemotactic protein-4: tissue-specific expression and signaling through CC chemokine receptor-2.  
J Leukoc Biol. 1997 Mar;61(3):353-60.  
PMID: 9060459 [PubMed - indexed for MEDLINE]
- ☐ **9:** [Raport CJ, Schweickart VL, Chantry D, Eddy RL Jr, Shows TB, Godiska R, Gray PW.](#) Related Articles, Links  
New members of the chemokine receptor gene family.  
J Leukoc Biol. 1996 Jan;59(1):18-23. Review.  
PMID: 8558062 [PubMed - indexed for MEDLINE]
- ☐ **10:** [Godiska R, Chantry D, Dietsch GN, Gray PW.](#) Related Articles, Links  
Chemokine expression in murine experimental allergic encephalomyelitis.  
J Neuroimmunol. 1995 May;58(2):167-76.  
PMID: 7539012 [PubMed - indexed for MEDLINE]
- ☐ **11:** [Schweickart VL, Raport CJ, Godiska R, Byers MG, Eddy RL Jr, Shows TB, Gray PW.](#) Related Articles, Links  
Cloning of human and mouse EBI1, a lymphoid-specific G-protein-coupled receptor encoded on human chromosome 17q12-q21.2.  
Genomics. 1994 Oct;23(3):643-50.  
PMID: 7851893 [PubMed - indexed for MEDLINE]
- ☐ **12:** [Godiska R, James C, Yao MC.](#) Related Articles, Links  
A distant 10-bp sequence specifies the boundaries of a programmed DNA deletion in Tetrahymena.  
Genes Dev. 1993 Dec;7(12A):2357-65.  
PMID: 8253382 [PubMed - indexed for MEDLINE]
- ☐ **13:** [Seyfried CE, Schweickart VL, Godiska R, Gray PW.](#) Related Articles, Links  
The human platelet-activating factor receptor gene (PTAFR) contains no introns and maps to chromosome 1.  
Genomics. 1992 Jul;13(3):832-4.  
PMID: 1322356 [PubMed - indexed for MEDLINE]
- ☐ **14:** [Godiska R, Yao MC.](#) Related Articles, Links  
A programmed site-specific DNA rearrangement in Tetrahymena thermophila requires flanking polypurine tracts.  
Cell. 1990 Jun 29;61(7):1237-46.  
PMID: 2364428 [PubMed - indexed for MEDLINE]
- ☐ **15:** [Godiska R, Aufderheide KJ, Gilley D, Hendrie P, Fitzwater T, Preer LB, Polisky B, Preer JR Jr.](#) Related Articles, Links  
Transformation of Paramecium by microinjection of a cloned serotype gene.  
Proc Natl Acad Sci U S A. 1987 Nov;84(21):7590-4.

PMID: 2823267 [PubMed - indexed for MEDLINE]

☐ 16: [Godiska R.](#)[Related Articles, Links](#)

Structure and sequence of the H surface protein gene of Paramecium and comparison with related genes.

Mol Gen Genet. 1987 Jul;208(3):529-36.

PMID: 3478550 [PubMed - indexed for MEDLINE]

Display	Summary	▼	Sort	▼	Save	Text	Clip Add	Order
Show:	20	▼	Items 1-16 of 16				One page.	

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1648BQL

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock  
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area  
NEWS 4 Apr 09 ZDB will be removed from STN  
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and  
IFIUDB  
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and  
ZCAPLUS  
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER  
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available  
NEWS 9 Jun 03 New e-mail delivery for search results now available  
NEWS 10 Jun 10 MEDLINE Reload  
NEWS 11 Jun 10 PCTFULL has been reloaded  
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment  
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;  
saved answer sets no longer valid  
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY  
NEWS 15 Jul 30 NETFIRST to be removed from STN  
NEWS 16 Aug 08 CANCERLIT reload  
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN  
NEWS 18 Aug 08 NTIS has been reloaded and enhanced  
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)  
now available on STN  
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded  
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded  
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced  
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced  
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file  
NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS  
NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA  
NEWS 27 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985  
NEWS 28 Oct 21 EVENTLINE has been reloaded  
NEWS 29 Oct 24 BEILSTEIN adds new search fields  
NEWS 30 Oct 24 Nutraceuticals International (NUTRACEUT) now available on  
STN  
NEWS 31 Oct 25 MEDLINE SDI run of October 8, 2002  
NEWS 32 Nov 18 DKILIT has been renamed APOLLIT  
NEWS 33 Nov 25 More calculated properties added to REGISTRY  
  
NEWS EXPRESS October 14 CURRENT WINDOWS VERSION IS V6.01,  
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),  
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:18:56 ON 25 NOV 2002

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 09:19:05 ON 25 NOV 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Nov 2002 VOL 137 ISS 22

FILE LAST UPDATED: 24 Nov 2002 (20021124/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> allergy and CCR4

29160 ALLERGY

2264 ALLERGIES

29817 ALLERGY

(ALLERGY OR ALLERGIES)

339 CCR4

L1 20 ALLERGY AND CCR4

=> allergy and MDC

29160 ALLERGY

2264 ALLERGIES

29817 ALLERGY

(ALLERGY OR ALLERGIES)  
 587 MDC  
 42 MDCS  
 610 MDC  
 (MDC OR MDCS)  
 L2 12 ALLERGY AND MDC

=> treatment and L1  
 1721072 TREATMENT  
 160234 TREATMENTS  
 1809421 TREATMENT  
 (TREATMENT OR TREATMENTS)  
 L3 6 TREATMENT AND L1

=> treatment and L2  
 1721072 TREATMENT  
 160234 TREATMENTS  
 1809421 TREATMENT  
 (TREATMENT OR TREATMENTS)  
 L4 2 TREATMENT AND L2

=> DIS L4 1- IBIB ABS  
 YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):Y  
 THE ESTIMATED COST FOR THIS REQUEST IS 4.58 U.S. DOLLARS  
 DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2001:526192 CAPLUS  
 DOCUMENT NUMBER: 135:117975  
 TITLE: Regulatory sequence for dendritic cell-specific  
 expression from human fascin genes and their use  
 INVENTOR(S): Reske-Kunz, Angelika; Ross, Xiaolan; Ross, Ralf;  
 Bros,  
 Matthias  
 PATENT ASSIGNEE(S): Germany  
 SOURCE: PCT Int. Appl., 117 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001051631	A2	20010719	WO 2001-EP362	20010112
WO 2001051631	A3	20020418		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 10001169	A1	20010726	DE 2000-10001169	20000113
EP 1250430	A2	20021023	EP 2001-903644	20010112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			DE 2000-10001169 A 20000113	

DE 2000-10010188 A 20000302

WO 2001-EP362 W 20010112

AB The invention relates to regulatory sequences which impart a specific expression in dendritic cells. The regulatory sequences are isolated from the human fascin gene and also comprise, for example, promoter sequences. The invention also relates to recombinant nucleic acid mols. and vectors, which contain the regulatory sequences, and to preferred embodiments of the recombinant nucleic acid mols. and vectors, which code the antigens or immunoregulatory proteins. The invention addnl. relates to host cells, which contain the recombinant nucleic acid mols. or vectors, and to methods for the prodn. thereof. Addnl. embodiments relate to in-vitro methods for stimulating T cells and for producing T cell-stimulating dendritic cells, and to their formulation as medicaments. Addnl. medicaments are described which essentially relate to DNA vaccines and to gene-therapeutic medicaments, for example, for the immunization against and for the **treatment** of infectious diseases, tumors, **allergies**, Creutzfeldt-Jakob plaques or Alzheimer plaques. Addnl. inventive medicaments can be used for the targeted modulation of immune responses that is imparted by dendritic cells, for example, for treating autoimmune diseases or transplant rejection. Finally, the invention relates to different uses of the regulatory sequences. Cloning of the gene and anal. of the 5'-flanking region using a luciferase reporter gene are described.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:223049 CAPLUS

DOCUMENT NUMBER: 130:251233

TITLE: Macrophage-derived chemokine (**MDC**),  
**MDC** analogs, **MDC** inhibitor

INVENTOR(S): substances, and their therapeutic applications  
Gray, Patrick W.; Chantry, David H.; Deeley, Michael C.; Raport, Carol J.; Godiska, Ronald

PATENT ASSIGNEE(S): Icos Corporation, USA

SOURCE: PCT Int. Appl., 159 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9915666	A2	19990401	WO 1998-US20270	19980928
WO 9915666	A3	19990916		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, US, US, US, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CN 1163635	A	19971029	CN 1996-190875	19960607
US 5932703	A	19990803	US 1996-660542	19960607
CA 2302806	AA	19990401	CA 1998-2302806	19980928
AU 9897778	A1	19990412	AU 1998-97778	19980928
EP 1017818	A2	20000712	EP 1998-951961	19980928

R: AT, BE, CH, DE, ES, FR, GB, IT, LI, SE, IE  
 PRIORITY APPLN. INFO.: US 1995-479620 A2 19950607  
 US 1995-558658 A2 19951116  
 US 1996-660542 A2 19960607  
 US 1997-939107 A2 19970926  
 US 1998-67447 A2 19980428  
 WO 1998-US20270 W 19980928

AB The present invention provides purified and isolated polynucleotide sequences encoding a novel macrophage-derived C-C chemokine designated "Macrophage Derived Chemokine" (MDC), and polypeptide fragments and analogs thereof. MDC cDNA sequences and their deduced amino acid sequences are provided from human, mouse, rat, and macaque. Also provided are materials and methods for the recombinant or synthetic prodn.

of the chemokine, fragments, and analogs; and purified and isolated chemokine protein, and polypeptide fragments and analogs thereof. Also provided are antibodies reactive with the chemokine and methods of making and using all of the foregoing. Also provided are assays for identifying modulators of MDC chemokine activity. MDC possesses antiproliferative activity against HIV-1 virus, stimulates fibroblast proliferation, inhibits tumor growth, induces chemotaxis of TH2 helper T cells, and modulates platelet aggregation, and is shown to be a high-affinity ligand for CCR4.

=> DIS L3 1- IBIB ABS

YOU HAVE REQUESTED DATA FROM 6 ANSWERS - CONTINUE? Y/(N):Y  
 THE ESTIMATED COST FOR THIS REQUEST IS 13.73 U.S. DOLLARS  
 DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L3 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:832576 CAPLUS  
 TITLE: **Treatment** of respiratory and lung diseases  
 with antisense oligonucleotides and a bronchodilating agent  
 INVENTOR(S): Nyce, Jonathan W.; Li, Yukui; Sandrasagra, Anthony;  
 Katz, Evan; Pabalan, Jonathan; Aguilar, Douglas;  
 Miller, Shoreh; Tang, Lei; Shahabuddin, Syed  
 PATENT ASSIGNEE(S): Epigenesis Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 764 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085309	A2	20021031	WO 2002-US13143	20020423
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2001-286036P P 20010424



AB This patent relates to a compn. comprising a carrier, oligonucleotides (oligos) that are antisense to adenosine receptors, and contain low amts. of or no adenosine (A), plus bronchodilating agents. All antisense oligonucleotides designed in accordance with the invention were highly effective at countering or reducing effects mediated by the receptors to which they are targeted. Two antisense phosphorothioated oligos

targeting

human adenosine A1 receptor mRNA, one targeting adenosine A2b receptor, and two targeting an A3 receptor are capable of countering the effect of exogenously administered adenosine which is mediated by the specific receptor they are targeted to. The activity of the antisense oligos are specific to the target and substitutively fail to inhibit another target. An oligonucleotide wherein the phosphodiester bonds are substituted with phosphorothioate bonds evidenced an unexpected superiority over the phosphodiester antisense oligo. In addn., they result in extremely low

or

non-existent deleterious side effects or toxicity. This represents 100% success in providing agents that are highly effective and specific in the **treatment** of bronchoconstriction and/or inflammation. These agents and the compn. and formulations provided are suitable for the **treatment** of respiratory tract, pulmonary and malignant diseases assocd. with bronchoconstriction, respiratory tract inflammation and **allergies**, impaired airways, including lung disease and diseases whose secondary effects afflict the lungs of a subject, such as **allergies**, asthma, impeded respiration, allergic rhinitis, pain, cystic fibrosis, pulmonary fibrosis, RDA, COPD, and cancers, among others.

The present agents and compn. may be administered preventatively, prophylactically or therapeutically in conjunction with other therapies, or may be utilized as a substitute for therapies that have significant, neg. side effects. The method of the present invention is also practiced with antisense oligonucleotides targeted to many genes, mRNAs and their corresponding proteins in essential the same manner.

L3 ANSWER 2.OF 6 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:832575 CAPLUS

TITLE: **Treatment** of respiratory and lung diseases with antisense oligonucleotides and a bronchodilating agent

INVENTOR(S): Nyce, Jonathan W.; Li, Yukui; Sandrasagra, Anthony; Katz, Evan; Pabalan, Jonathan; Aguilar, Douglas; Miller, Shoreh; Tang, Lei; Shahabuddin, Syed

PATENT ASSIGNEE(S): Epigenesis Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 872 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085308	A2	20021031	WO 2002-US13135	20020423

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 WO 2002085308 A2 20021031 WO 2002-XA13135 20020423  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 WO 2002085308 A2 20021031 WO 2002-XB13135 20020423  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 WO 2002085308 A2 20021031 WO 2002-XC13135 20020423  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 PRIORITY APPLN. INFO.: US 2001-286137P P 20010424  
 WO 2002-US13135 A 20020423  
 AB This patent relates to a compn. comprising a carrier, oligonucleotides (oligos) that are antisense to adenosine receptors, and contain low amts. of or no adenosine (A), plus bronchodilating agents. All antisense oligonucleotides designed in accordance with the invention were highly effective at countering or reducing effects mediated by the receptors to which they are targeted. Two antisense phosphorothioated oligos targeting human adenosine A1 receptor mRNA, one targeting adenosine A2b receptor, and two targeting an A3 receptor are capable of countering the effect of exogenously administered adenosine which is mediated by the specific receptor they are targeted to. The activity of the antisense oligos are specific to the target and substitutively fail to inhibit another target. An oligonucleotide wherein the phosphodiester bonds are substituted with phosphorothioate bonds evidenced an unexpected superiority over the phosphodiester antisense oligo. In addn., they result in extremely low or non-existent deleterious side effects or toxicity. This represents 100% success in providing agents that are highly effective and specific in the **treatment** of bronchoconstriction and/or inflammation. **Treatment** with antisense oligonucleotides in combination with anti-inflammatory steroid and/or ubiquinones is also provided. These agents and the compn. and formulations provided are suitable for the

**treatment** of respiratory tract, pulmonary and malignant diseases assocd. with bronchoconstriction, respiratory tract inflammation and **allergies**, impaired airways, including lung disease and diseases whose secondary effects afflict the lungs of a subject, such as **allergies**, asthma, impeded respiration, allergic rhinitis, pain, cystic fibrosis, pulmonary fibrosis, RDA, COPD, and cancers, among others.

The present agents and compn. may be administered preventatively, prophylactically or therapeutically in conjunction with other therapies, or may be utilized as a substitute for therapies that have significant, neg. side effects. The method of the present invention is also practiced with antisense oligonucleotides targeted to many genes, mRNAs and their corresponding proteins in essential the same manner.

L3 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:756484 CAPLUS

DOCUMENT NUMBER: 133:329593

TITLE: Low adenosine anti-sense oligonucleotide, compositions, kit and method for **treatment** of airway disorders associated with bronchoconstriction, lung inflammation, **allergy**(ies) and surfactant depletion

INVENTOR(S): Nyce, Jonathan W.

PATENT ASSIGNEE(S): East Carolina University, USA

SOURCE: PCT Int. Appl., 1592 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000062736	A2	20001026	WO 2000-US8020	20000324
WO 2000062736	A3	20011011		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
BR 2000006019	A	20010313	BR 2000-6019	20000324
EP 1168919	A2	20020109	EP 2000-919668	20000324
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

PRIORITY APPLN. INFO.: US 1999-127958P P 19990406

WO 2000-US8020 W 20000324

OTHER SOURCE(S): MARPAT 133:329593

AB An in vivo method of selectively delivering a nucleic acid to a target gene or mRNA, comprises the topical administration, e.g. to the respiratory system, of a subject of a therapeutic amt. of an oligonucleotide (oligo) that is antisense to the initiation codon region, the coding region, the 5' or 3' intron-exon junctions or regions within 2 to 10 nucleotides of the junctions of the gene or antisense to a mRNA complementary to the gene in an amt. effective to reach the target polynucleotide and reducing or inhibiting expression. In addn. a method of treating an adenosine-mediated effect comprises topically administering

to a subject an antisense oligo in an amt. effective to treat the respiratory, pulmonary, or airway disease. In order to minimize triggering adenosine receptors by their metab., the administered oligos have a low content of or are essentially free of adenosine. A pharmaceutical compn. and formulations comprise the oligo antisense to an adenosine receptor, genes and mRNAs encoding them, genomic and mRNA flanking regions, intron and exon borders and all regulatory and functionally related segments of the genes and mRNAs encoding the polypeptides, their salts and mixts. Various formulations contain a requisite carrier, and optionally other additives and biol. active agents.

The low-adenosine or adenosine-free (des-A) agent for practicing the method of the invention may be prepd. by selecting a target gene(s), genomic flanking region(s), RNA(s) and/or polypeptide(s) assocd. with a disease(s) or condition(s) afflicting lung airways, obtaining the sequence

of the mRNA(s) corresponding to the target gene(s) and/or genomic flanking

region(s), and/or RNAs encoding the target polypeptide(s), selecting at least one segment of the mRNA which may be up to 60 % free of thymidine (T) and synthesizing one or more anti-sense oligonucleotide(s) to the

mRNA

segments which are free of adenosine (A) by substituting a universal base for A when present in the oligonucleotide. The agent may be prepd. by selection of target nucleic acid sequences with GC running stretches, which have low T content, and by optionally replacing A in the antisense oligonucleotides with a "Universal or alternative base". The agent, compn. and formulations are used for prophylactic, preventive and therapeutic **treatment** of ailments assocd. with impaired respiration, lung **allergy**(ies) and/or inflammation and depletion lung surfactant or surfactant hypoprodn., such as pulmonary vasoconstriction, inflammation, **allergies**, allergic rhinitis, asthma, impeded respiration, lung pain, cystic fibrosis, bronchoconstriction. The present **treatment** is suitable for administration in combination with other **treatments**, e.g. before, during and after other **treatments**, including radiation, chemotherapy, antibody therapy and surgery, among others. Alternatively, the present agent is effectively administered prophylactically or therapeutically by itself for conditions without known therapies or as a substitute for therapies exhibiting undesirable side effects. The **treatment** of this invention may be administered directly into the respiratory system of a subject so that the agent has direct access to

the

lungs, or by other effective routes of administration, e.g. topically, transdermally, by implantation, etc., in an amt. effective to reduce or inhibit the symptoms of the ailment.

L3 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:628006 CAPLUS

DOCUMENT NUMBER: 133:217723

TITLE: Method for validating/invalidating target(s) and pathways

INVENTOR(S): Nyce, Jonathan W.

PATENT ASSIGNEE(S): Epigenesis Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2000051621	A1	20000908	WO 2000-US5643	20000302
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000009247	A	20011120	BR 2000-9247	20000302
EP 1165093	A1	20020102	EP 2000-913730	20000302
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002537792	T2	20021112	JP 2000-602288	20000302
PRIORITY APPLN. INFO.:			US 1999-122950P	P 19990305
			WO 2000-US5643	W 20000302
OTHER SOURCE(S): MARPAT 133:217723				
AB A method of detg. the existence of a correlation between a function of a disease or condition and a gene or mRNA encoding a target polypeptide suspected of being assocd. with a disease or condition, comprises obtaining oligonucleotides (oligos) consisting of up to about 15 % adenosine (A), preferably having no adenosine content, and which is anti-sense to a target selected from the group consisting of target genes and their corresponding mRNAs, genomic and mRNA flanking regions selected from the group consisting of 3' and 5' intron-exon borders and the juxta-section between coding and non-coding regions, and all mRNA segments encoding polypeptides assocd. with a pre-selected disease or condition; selecting amongst the oligos one that significantly inhibits or ablates expression of the polypeptide encoded by the mRNA upon in vitro hybridization to the target mRNA; administering to a subject an amt. of the selected oligo effective for in vivo hybridization to the target mRNA; and assessing a subject's function that is assocd. with the disease or condition before and after administration of the oligo; wherein a change in the function's value greater than about 70% indicates a pos. correlation, between about 40 and about 70% a possible correlation, and below about 30% a lack of correlation. The present method preferably administers the oligos in situ where the target is located, e.g. into the subject's respiration when validating targets assocd. with malignant and other pulmonary and respiratory functions, so that the agent has direct access to the lungs. Alternatively, such desAdenosine oligos may be delivered directly to the CNS or other organs, tissues and organ systems, by known delivery formulations. This invention provides a rapid, reliable method for drug target validation/invalidation in various biol. systems that utilize proprietary low or desAdenosine antisense oligonucleotides. Using desAdenosine antisense oligonucleotides, the present method may validate/invalidate potential gene targets with a level of speed and accuracy that has heretofore been impossible using traditional techniques. The use of antisense oligonucleotides to target adenosine receptors is described. Adenosine A1 receptor antisense oligonucleotides had bronchodilator activity in rabbits and adenosine A3 receptor antisense oligonucleotides had anti-inflammatory activity in asthmatic rabbits.				
REFERENCE COUNT:		3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS	

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L3 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:223049 CAPLUS

DOCUMENT NUMBER: 130:251233

TITLE: Macrophage-derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and their therapeutic applications

INVENTOR(S): Gray, Patrick W.; Chantry, David H.; Deeley, Michael C.; Raport, Carol J.; Godiska, Ronald

PATENT ASSIGNEE(S): Icos Corporation, USA

SOURCE: PCT Int. Appl., 159 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9915666	A2	19990401	WO 1998-US20270	19980928
WO 9915666	A3	19990916		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, US, US, US, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CN 1163635	A	19971029	CN 1996-190875	19960607
US 5932703	A	19990803	US 1996-660542	19960607
CA 2302806	AA	19990401	CA 1998-2302806	19980928
AU 9897778	A1	19990412	AU 1998-97778	19980928
EP 1017818	A2	20000712	EP 1998-951961	19980928
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, SE, IE				
PRIORITY APPLN. INFO.:			US 1995-479620	A2 19950607
			US 1995-558658	A2 19951116
			US 1996-660542	A2 19960607
			US 1997-939107	A2 19970926
			US 1998-67447	A2 19980428
			WO 1998-US20270	W 19980928
AB The present invention provides purified and isolated polynucleotide sequences encoding a novel macrophage-derived C-C chemokine designated "Macrophage Derived Chemokine" (MDC), and polypeptide fragments and analogs thereof. MDC cDNA sequences and their deduced amino acid sequences are provided from human, mouse, rat, and macaque. Also provided are materials and methods for the recombinant or synthetic prodn. of the chemokine, fragments, and analogs; and purified and isolated chemokine protein, and polypeptide fragments and analogs thereof. Also provided are antibodies reactive with the chemokine and methods of making and using all of the foregoing. Also provided are assays for identifying modulators of MDC chemokine activity. MDC possesses antiproliferative activity against HIV-1 virus, stimulates fibroblast proliferation, inhibits tumor growth, induces chemotaxis of TH2 helper T cells, and modulates platelet				

PATENT ASSIGNEE(S): Germany  
 SOURCE: PCT Int. Appl., 117 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001051631	A2	20010719	WO 2001-EP362	20010112
WO 2001051631	A3	20020418		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 10001169	A1	20010726	DE 2000-10001169	20000113
EP 1250430	A2	20021023	EP 2001-903644	20010112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.: DE 2000-10001169 A 20000113 DE 2000-10010188 A 20000302 WO 2001-EP362 W 20010112				

AB The invention relates to regulatory sequences which impart a specific expression in dendritic cells. The regulatory sequences are isolated from the human fascin gene and also comprise, for example, promoter sequences. The invention also relates to recombinant nucleic acid mols. and vectors, which contain the regulatory sequences, and to preferred embodiments of the recombinant nucleic acid mols. and vectors, which code the antigens or immunoregulatory proteins. The invention addnl. relates to host cells, which contain the recombinant nucleic acid mols. or vectors, and to methods for the prodn. thereof. Addnl. embodiments relate to in-vitro methods for stimulating T cells and for producing T cell-stimulating dendritic cells, and to their formulation as medicaments. Addnl. medicaments are described which essentially relate to DNA vaccines and to gene-therapeutic medicaments, for example, for the immunization against and for the treatment of infectious diseases, tumors, **allergies**, Creutzfeldt-Jakob plaques or Alzheimer plaques. Addnl. inventive medicaments can be used for the targeted modulation of immune responses that is imparted by dendritic cells, for example, for treating autoimmune diseases or transplant rejection. Finally, the invention relates to different uses of the regulatory sequences. Cloning of the gene and anal. of the 5'-flanking region using a luciferase reporter gene are described.

L2 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2001:402803 CAPLUS  
 DOCUMENT NUMBER: 136:84180  
 TITLE: Chemokines, chemokine receptors and **allergy**  
 AUTHOR(S): Kaplan, Allen P.  
 CORPORATE SOURCE: Division of Pulmonary Diseases and Central Case Medicine and Allergy and, Medical University of South Carolina, Charleston, SC, USA

NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,  
 UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,  
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,  
 CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2304312	AA	19990325	CA 1998-2304312	19980917
AU 9893951	A1	19990405	AU 1998-93951	19980917
AU 752531	B2	20020919		
EP 1019065	A1	20000719	EP 1998-947089	19980917

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,

FI

BR 9812650	A	20000822	BR 1998-12650	19980917
------------	---	----------	---------------	----------

PRIORITY APPLN. INFO.: US 1997-59160P P 19970917  
 US 1998-93972 A 19980609  
 WO 1998-US19419 W 19980917

AB Antisense oligonucleotides carrying sequences that will allow them to bind to more than one mRNA in a target cell are described. Such oligonucleotides can be used as a single treatment for diseases having more than one contributing pathway. In particular, oligonucleotides effective against genes involved in the etiol. of respiratory disease are targeted. Preferably, the oligonucleotides are low in adenosine (.1 to req. 15%) and may have adenosines substituted with analogs. These oligonucleotides are targeted to high (G+C) sequences within mRNAs.

Thus, phosphorothioate antisense oligonucleotide (HAdA1AS, 5'-gatggagggcgcatggcggg-3') designed for the adenosine A1 receptor is provided. HAdA1AS significantly and specifically reduces the in vivo response to adenosine challenge in a dose-dependent manner, is effective in protection against aeroallergen-induced bronchoconstriction (house dust mite), has an unexpected long-term duration of effect (8.3 days for both PC50 adenosine and resistance), and is free of side effects that might be toxic to the recipient. Such oligonucleotides may be used for treating a disease or condition associated with lung airway, such as bronchoconstriction, inflammation, or allergies.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

=> log off  
 ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF  
 LOGOFF? (Y)/N/HOLD:y  
 STN INTERNATIONAL LOGOFF AT 09:21:40 ON 25 NOV 2002



aggregation, and is shown to be a high-affinity ligand for CCR4.

L3 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:219995 CAPLUS

DOCUMENT NUMBER: 130:306599

TITLE: Antisense oligonucleotides capable of binding to multiple targets and their use in the **treatment** of respiratory disease

INVENTOR(S): Nyce, Jonathan W.

PATENT ASSIGNEE(S): East Carolina University, USA

SOURCE: PCT Int. Appl., 120 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9913886	A1	19990325	WO 1998-US19419	19980917
W:				
AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:				
GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2304312	AA	19990325	CA 1998-2304312	19980917
AU 9893951	A1	19990405	AU 1998-93951	19980917
AU 752531	B2	20020919		
EP 1019065	A1	20000719	EP 1998-947089	19980917
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				

FI

BR 9812650	A	20000822	BR 1998-12650	19980917
PRIORITY APPLN. INFO.:			US 1997-59160P	P 19970917
			US 1998-93972	A 19980609
			WO 1998-US19419	W 19980917

AB Antisense oligonucleotides carrying sequences that will allow them to bind

to more than one mRNA in a target cell are described. Such oligonucleotides can be used as a single **treatment** for diseases having more than one contributing pathway. In particular, oligonucleotides effective against genes involved in the etiol. of respiratory disease are targeted. Preferably, the oligonucleotides are low in adenosine (.ltoreq.15%) and may have adenosines substituted with analogs. These oligonucleotides are targeted to high (G+C) sequences within mRNAs. Thus, phosphorothioate antisense oligonucleotide (HAdA1AS, 5'-gatggagggcgcatggcg-3') designed for the adenosine A1 receptor is provided. HAdA1AS significantly and specifically reduces the in vivo response to adenosine challenge in a dose-dependent manner, is effective in protection against aeroallergen-induced bronchoconstriction (house dust mite), has an unexpected long-term duration of effect (8.3 days for both PC50 adenosine and resistance), and is free of side effects that might be toxic to the recipient. Such oligonucleotides may be used for treating a disease or condition assocd. with lung airway, such as bronchoconstriction, inflammation, or **allergies**.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

=> DIS L2 1- IBIB ABS

YOU HAVE REQUESTED DATA FROM 12 ANSWERS - CONTINUE? Y/(N):Y

THE ESTIMATED COST FOR THIS REQUEST IS 27.47 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L2 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:549831 CAPLUS

DOCUMENT NUMBER: 137:139275

TITLE: Nickel-specific CD4+ and CD8+ T cells display  
distinct

migratory responses to chemokines produced during  
allergic contact dermatitis

AUTHOR(S): Sebastiani, Silvia; Albanesi, Cristina; Nasorri,  
Francesca; Girolomoni, Giampiero; Cavani, Andrea

CORPORATE SOURCE: Laboratory of Immunology, Istituto Dermopatico  
dell'Immacolata, IRCCS, Rome, 00167, Italy

SOURCE: Journal of Investigative Dermatology (2002), 118(6),  
1052-1058

CODEN: JIDEAE; ISSN: 0022-202X

PUBLISHER: Blackwell Publishing, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Development of allergic contact dermatitis to haptens depends upon a  
balance between CD8+ T lymphocytes with pathogenic activity and CD4+ T  
cells, which comprise both effector and regulatory cells. Thus,  
differential recruitment of CD8+ and CD4+ lymphocytes to sites of hapten  
challenge may have considerable impact on disease expression. Here the  
migration of cutaneous lymphocyte-assocd. antigen+, nickel-specific CD8+  
and CD4+ T cell lines were compared with a panel of chemokines produced

in the skin during allergic contact dermatitis. CCL17/TARC and CCL22/  
**MDC** induced a 3-fold higher migration of CD4+ compared with CD8+  
lymphocytes. In contrast, CXCL10/IP-10 was 2-fold more potent in  
attracting CD8+ cells. These findings were consistent with the higher  
expression of CCR4 and CXCR3 on CD4+ and CD8+ T cell lines, resp.  
Moreover, CCR4 expression was high on nickel-specific T helper 2,  
intermediate on T helper 1 and T cytotoxic 2, and almost undetectable on

T cytotoxic 1 clones. On the contrary, CXCR3 was expressed by T cytotoxic

1 and 2 and T helper 1, but not T helper 2 clones. Reverse  
transcription-polymerase chain reaction anal. of the skin before and

after hapten challenge revealed the constitutive presence of TARC, and the

early appearance of CCL2/MCP-1, followed by IP-10, CCL4/MIP-1.beta., and  
**MDC** mRNA. Supernatants from activated keratinocytes induced a  
strong migration of CD8+ lymphocytes, which was blocked by neutralization  
of IP-10. Conversely, supernatants from immature and mature dendritic  
cells attracted mostly CD4+ lymphocytes in a TARC- and **MDC**  
-dependent manner. Our data indicate that distinct chemokines and cell  
types control the accumulation of CD8+ and CD4+ T cells within inflamed  
skin.

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR  
THIS

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L2 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:479577 CAPLUS

DOCUMENT NUMBER: 137:92625

TITLE: Human epithelial cells trigger dendritic  
cell-mediated

AUTHOR(S): Soumelis, Vassili; Reche, Pedro A.; Kanzler, Holger;  
Yuan, Wei; Edward, Gina; Homey, Bernhart; Gilliet,  
Michel; Ho, Steve; Antonenko, Svetlana; Lauerma,  
Annti; Smith, Kathleen; Gorman, Daniel; Zurawski,  
Sandra; Abrams, Jon; Menon, Satish; McClanahan,

Terri;

de Waal-Malefyt, Rene; Bazan, Fernando; Kastelein,  
Robert A.; Liu, Yong-Jun

CORPORATE SOURCE: DNAX, Palo Alto, CA, 94304, USA

SOURCE: Nature Immunology (2002), 3(7), 673-680

CODEN: NIAMCZ; ISSN: 1529-2908

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Whether epithelial cells play a role in triggering the immune cascade  
leading to T helper 2 (TH2)-type allergic inflammation is not known. We  
show here that human thymic stromal lymphopoietin (TSLP) potentially  
activated CD11c+ dendritic cells (DCs) and induced prodn. of the  
TH2-attracting chemokines TARC (thymus and activation-regulated  
chemokine;  
also known as CCL17) and MDC (macrophage-derived chemokine;  
CCL22). TSLP-activated DCs primed naive TH cells to produce the  
proallergic cytokines interleukin 4 (IL-4), IL-5, IL-13 and tumor  
necrosis  
factor-.alpha., while down-regulating IL-10 and interferon-.gamma.. TSLP  
was highly expressed by epithelial cells, esp. keratinocytes from  
patients  
with atopic dermatitis. TSLP expression was assocd. with Langerhans cell  
migration and activation in situ. These findings shed new light on the  
function of human TSLP and the role played by epithelial cells and DCs in  
initiating allergic inflammation.

REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR  
THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L2 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:429201 CAPLUS

DOCUMENT NUMBER: 137:4997

TITLE: Method for diagnosing allergic diseases using DNA and  
protein microarray technology

INVENTOR(S): Schmidt-Weber, Carsten; Blaser, Kurt; Wohlfahrt, Jan

PATENT ASSIGNEE(S): Genescan Europe Ag, Germany

SOURCE: PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002044732	A2	20020606	WO 2001-EP13937	20011129
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1221618 A1 20020710 EP 2000-126117 20001129

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

AU 2002021906 A5 20020611 AU 2002-21906 20011129

PRIORITY APPLN. INFO.: EP 2000-126117 A 20001129  
WO 2001-EP13937 W 20011129

AB MRNA of activated lymphocytes such as CD4+ T cells allows differential diagnosis of allergic diseases. The CD4+ T cells are isolated and stimulated under defined conditions in vitro. Subsequently, mRNA is subjected to multigene anal. such as DNA arrays. Expression profiling images, such as gene expression profiles, can be created, which allow on the basis of the activated T cell mRNA the prediction of certain phenotypes such as asthma or atopic dermatitis.

L2 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:354656 CAPLUS

DOCUMENT NUMBER: 137:31703

TITLE: Cytokines and chemoattractants in allergic inflammation

AUTHOR(S): Romagnani, S.

CORPORATE SOURCE: Department of Internal Medicine, and Respiratory Diseases, Allergy, Section of Clinical Immunology, University of Florence, Florence, 50134, Italy

SOURCE: Molecular Immunology (2002), 38(12-13), 881-885  
CODEN: MOIMD5; ISSN: 0161-5890

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. It is now generally accepted that type 2 T helper (Th2) cytokines and some chemoattractants play an essential role in the pathogenesis of the allergic inflammation. The effects of Th2 cytokines, such as interleukin (IL)-4, IL-5, IL-9, and IL-13, account for virtually all the pathophysiol. manifestations of allergy and asthma. Moreover, both Th2 cells and the effector cells usually present in the areas of allergic inflammation (basophils, mast cells, and eosinophils) express chemoattractant receptors, such as CCR3, CCR4, CCR8, and CRTH2. Therefore, interactions of eotaxin(s), eotaxin/CCL11, RANTES/CCL5, and MCP-1/CCL2, MCP-2/CCL8, MCP-3/CCL7, MCP-4/CCL13 with CCR3 are responsible for the recruitment of basophils, eosinophils and mast cells, whereas interactions of CCR4 with MDC/CCL22 or TARC/CCL17, CCR8 with I-309/CCL1, and CRTH2 with PGD2 play a crit. role in the allergen-induced recruitment of Th2 cells in the target tissues of allergic inflammation. The demonstration that Th2-polarized responses against allergens represent the triggering event for the development of allergic diseases, together with the recognition that some chemoattractants are responsible for the recruitment of both Th2 cells and other effector cells of allergic inflammation, can provide the conceptual basis for the development of new therapeutic strategies in allergic conditions.

REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L2 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:693651 CAPLUS  
DOCUMENT NUMBER: 135:240908  
TITLE: Assay for agents that induce chemokinesis  
INVENTOR(S): Carson, Dennis A.; Leoni, Lorenzo M.; Cottam, Howard B.  
PATENT ASSIGNEE(S): Regents of the University of California, USA  
SOURCE: PCT Int. Appl., 48 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001069240	A1	20010920	WO 2001-US8581	20010316
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002010125	A1	20020124	US 2001-810010	20010316
PRIORITY APPLN. INFO.:		US 2000-189976P P 20000316		
AB The present invention provides methods for identifying compds. that can induce cellular chemokinesis. According to the present invention, chemokinesis interferes with immune and inflammatory responses by increasing cell movements and altering cell migration patterns. Surprisingly, compds. isolated according to the present invention can interfere with the spread of malignant cells through the body, reduce inflammatory responses and can cause leukocytes to be retained in lymph nodes, the spleen and other organs of the reticulo-endothelial system. Several methods are contemplated by the present invention for identifying compds. which can induce chemokinesis. In one embodiment the method involves contacting a population of target cells with a test compd. and observing whether the target cells produce a chemotactic mol.; wherein				
the target cell has a cognate receptor for the chemotactic mol. In another embodiment, the method involves contacting a population of target cells with a test compd. and observing whether the targets cells homotypically aggregate. In yet another embodiment, the method involves contacting a population of target cells with a test compd. and observing whether actin filaments in the target cells form stress fibers.				
REFERENCE COUNT:	4	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE		

FORMAT

L2 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:526192 CAPLUS  
DOCUMENT NUMBER: 135:117975  
TITLE: Regulatory sequence for dendritic cell-specific expression from human fascin genes and their use  
INVENTOR(S): Reske-Kunz, Angelika; Ross, Xiaolan; Ross, Ralf; Bros,  
Matthias



DOCUMENT NUMBER: 132:48648  
 TITLE: Chemokines fundamental to the inflammation associated with allergic disorders  
 AUTHOR(S): Hirai, Koichi  
 CORPORATE SOURCE: Dep. of Bioregul. and Funct., Univ. of Tokyo Grad. Sch. of Med., Japan  
 SOURCE: Saishin Igaku (1999), 54(12), 2884-2887  
 CODEN: SAIGAK; ISSN: 0370-8241  
 PUBLISHER: Saishin Igakusha  
 DOCUMENT TYPE: Journal; General Review  
 LANGUAGE: Japanese

AB A review, with 19 refs., on expression of chemokine receptors on eosinophils, increased expression of eotaxin in allergic inflammation sites of human, cytokines regulating eotaxin expression, and CCR3 as a single receptor for eotaxin. Attempts of therapy for allergic inflammation by inhibiting TARC (thymus- and activation-regulated chemokine) and **MDC** (macrophage-derived chemokine) on Th2 cells are also discussed.

L2 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:223049 CAPLUS  
 DOCUMENT NUMBER: 130:251233  
 TITLE: Macrophage-derived chemokine (**MDC**), **MDC** analogs, **MDC** inhibitor substances, and their therapeutic applications  
 INVENTOR(S): Gray, Patrick W.; Chantry, David H.; Deeley, Michael C.; Raport, Carol J.; Godiska, Ronald  
 PATENT ASSIGNEE(S): Icos Corporation, USA  
 SOURCE: PCT Int. Appl., 159 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9915666	A2	19990401	WO 1998-US20270	19980928
WO 9915666	A3	19990916		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, US, US, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CN 1163635	A	19971029	CN 1996-190875	19960607
US 5932703	A	19990803	US 1996-660542	19960607
CA 2302806	AA	19990401	CA 1998-2302806	19980928
AU 9897778	A1	19990412	AU 1998-97778	19980928
EP 1017818	A2	20000712	EP 1998-951961	19980928
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, SE, IE				
PRIORITY APPLN. INFO.:			US 1995-479620	A2 19950607
			US 1995-558658	A2 19951116
			US 1996-660542	A2 19960607
			US 1997-939107	A2 19970926
			US 1998-67447	A2 19980428
			WO 1998-US20270	W 19980928

AB The present invention provides purified and isolated polynucleotide sequences encoding a novel macrophage-derived C-C chemokine designated "Macrophage Derived Chemokine" (MDC), and polypeptide fragments and analogs thereof. MDC cDNA sequences and their deduced amino acid sequences are provided from human, mouse, rat, and macaque. Also provided are materials and methods for the recombinant or synthetic prodn. of the chemokine, fragments, and analogs; and purified and isolated chemokine protein, and polypeptide fragments and analogs thereof. Also provided are antibodies reactive with the chemokine and methods of making and using all of the foregoing. Also provided are assays for identifying modulators of MDC chemokine activity. MDC possesses antiproliferative activity against HIV-1 virus, stimulates fibroblast proliferation, inhibits tumor growth, induces chemotaxis of TH2 helper T cells, and modulates platelet aggregation, and is shown to be a high-affinity ligand for CCR4.

=> DIS L1 1- IBIB ABS

YOU HAVE REQUESTED DATA FROM 20 ANSWERS - CONTINUE? Y/(N):Y  
THE ESTIMATED COST FOR THIS REQUEST IS 45.78 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:832576 CAPLUS

TITLE: Treatment of respiratory and lung diseases with antisense oligonucleotides and a bronchodilating agent

INVENTOR(S): Nyce, Jonathan W.; Li, Yukui; Sandrasagra, Anthony; Katz, Evan; Pabalan, Jonathan; Aguilar, Douglas; Miller, Shoreh; Tang, Lei; Shahabuddin, Syed

PATENT ASSIGNEE(S): Epigenesis Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 764 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085309	A2	20021031	WO 2002-US13143	20020423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CE, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2001-286036P P 20010424

AB This patent relates to a compn. comprising a carrier, oligonucleotides (oligos) that are antisense to adenosine receptors, and contain low amts. of or no adenosine (A), plus bronchodilating agents. All antisense oligonucleotides designed in accordance with the invention were highly effective at countering or reducing effects mediated by the receptors to which they are targeted. Two antisense phosphorothioated oligos targeting



human adenosine A1 receptor mRNA, one targeting adenosine A2b receptor, and two targeting an A3 receptor are capable of countering the effect of exogenously administered adenosine which is mediated by the specific receptor they are targeted to. The activity of the antisense oligos are specific to the target and substitutively fail to inhibit another target. An oligonucleotide wherein the phosphodiester bonds are substituted with phosphorothioate bonds evidenced an unexpected superiority over the phosphodiester antisense oligo. In addn., they result in extremely low

or

non-existent deleterious side effects or toxicity. This represents 100% success in providing agents that are highly effective and specific in the treatment of bronchoconstriction and/or inflammation. These agents and the compn. and formulations provided are suitable for the treatment of respiratory tract, pulmonary and malignant diseases assocd. with bronchoconstriction, respiratory tract inflammation and **allergies**, impaired airways, including lung disease and diseases whose secondary effects afflict the lungs of a subject, such as **allergies**, asthma, impeded respiration, allergic rhinitis, pain, cystic fibrosis, pulmonary fibrosis, RDA, COPD, and cancers, among others. The present agents and compn. may be administered preventatively, prophylactically or therapeutically in conjunction with other therapies, or may be utilized

as

a substitute for therapies that have significant, neg. side effects. The method of the present invention is also practiced with antisense oligonucleotides targeted to many genes, mRNAs and their corresponding proteins in essential the same manner.

L1 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:832575 CAPLUS

TITLE: Treatment of respiratory and lung diseases with antisense oligonucleotides and a bronchodilating

agent

INVENTOR(S): Nyce, Jonathan W.; Li, Yukui; Sandrasagra, Anthony; Katz, Evan; Pabalan, Jonathan; Aguilar, Douglas; Miller, Shoreh; Tang, Lei; Shahabuddin, Syed

PATENT ASSIGNEE(S): Epigenesis Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 872 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085308	A2	20021031	WO 2002-US13135	20020423
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002085308	A2	20021031	WO 2002-XA13135	20020423
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,			

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2002085308 A2 20021031 WO 2002-XB13135 20020423

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2002085308 A2 20021031 WO 2002-XC13135 20020423

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-286137P P 20010424  
WO 2002-US13135 A 20020423

AB This patent relates to a compn. comprising a carrier, oligonucleotides (oligos) that are antisense to adenosine receptors, and contain low amts. of or no adenosine (A), plus bronchodilating agents. All antisense oligonucleotides designed in accordance with the invention were highly effective at countering or reducing effects mediated by the receptors to which they are targeted. Two antisense phosphorothioated oligos targeting human adenosine A1 receptor mRNA, one targeting adenosine A2b receptor, and two targeting an A3 receptor are capable of countering the effect of exogenously administered adenosine which is mediated by the specific receptor they are targeted to. The activity of the antisense oligos are specific to the target and substitutively fail to inhibit another target. An oligonucleotide wherein the phosphodiester bonds are substituted with phosphorothioate bonds evidenced an unexpected superiority over the phosphodiester antisense oligo. In addn., they result in extremely low or non-existent deleterious side effects or toxicity. This represents 100% success in providing agents that are highly effective and specific in the treatment of bronchoconstriction and/or inflammation. Treatment with antisense oligonucleotides in combination with anti-inflammatory steroid and/or ubiquinones is also provided. These agents and the compn. and formulations provided are suitable for the treatment of respiratory tract, pulmonary and malignant diseases assocd. with bronchoconstriction, respiratory tract inflammation and **allergies**, impaired airways, including lung disease and diseases whose secondary effects afflict the lungs of a subject, such as **allergies**, asthma, impeded respiration, allergic rhinitis, pain, cystic fibrosis, pulmonary fibrosis,

RDA, COPD, and cancers, among others. The present agents and compn. may be administered preventatively, prophylactically or therapeutically in conjunction with other therapies, or may be utilized as a substitute for therapies that have significant, neg. side effects. The method of the present invention is also practiced with antisense oligonucleotides targeted to many genes, mRNAs and their corresponding proteins in essential the same manner.

L1 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:571773 CAPLUS

DOCUMENT NUMBER: 137:153743

TITLE: Airway hyperresponsiveness, but not airway remodeling,

is attenuated during chronic pulmonary allergic responses to *Aspergillus* in **CCR4**<sup>-/-</sup> mice

AUTHOR(S): Schuh, Jane M.; Power, Christine A.; Proudfoot, Amanda

E.; Kunkel, Steven L.; Lukacs, Nicholas W.; Hogaboam, Cory M.

CORPORATE SOURCE: Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA

SOURCE: FASEB Journal (2002), 16(10), 1313-1315, 10.1096/fj.02-0193fje

CODEN: FAJOEC; ISSN: 0892-6638

PUBLISHER: Federation of American Societies for Experimental Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The role of CC chemokine receptor 4 (**CCR4**) during the development and maintenance of Th2- type allergic airway disease is controversial. In this study, we examd. the role of **CCR4** in the chronic allergic airway response to live *Aspergillus fumigatus* spores, or conidia, in A. *fumigatus*-sensitized mice. After the conidia challenge, mice lacking **CCR4** (**CCR4**<sup>-/-</sup> mice) exhibited significantly increased nos. of airway neutrophils and macrophages, and conidia were more rapidly eliminated from these mice compared with control

**CCR4** wild-type (**CCR4**<sup>+/+</sup>) mice. Significant airway hyperresponsiveness to i.v. methacholine was obsd. at day 3 in **CCR4**<sup>-/-</sup> mice, whereas at days 7 and 30, airway hyperresponsiveness was attenuated in these mice compared with control mice. A major redn. in

peribronchial and airway eosinophilia was obsd. in **CCR4**<sup>-/-</sup> mice at all times after conidia challenge in contrast to **CCR4**<sup>+/+</sup> mice. Further, whole lung levels of interleukin (IL) 4 and IL-5 were significantly increased in **CCR4**<sup>-/-</sup> mice at day 3, whereas these Th2 cytokines and IL-13 were significantly decreased at day 30 in **CCR4**<sup>-/-</sup> mice compared with their wild-type counterparts. Peribronchial fibrosis and goblet cell hyperplasia were similar in both groups of mice throughout the course of this model. In summary, **CCR4** modulates both innate and acquired immune responses assocd. with chronic fungal asthma.

REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L1 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:549831 CAPLUS

DOCUMENT NUMBER: 137:139275

TITLE: Nickel-specific CD4+ and CD8+ T cells display  
distinct migratory responses to chemokines produced during  
allergic contact dermatitis  
AUTHOR(S): Sebastiani, Silvia; Albanesi, Cristina; Nasorri,  
Francesca; Girolomoni, Giampiero; Cavani, Andrea  
CORPORATE SOURCE: Laboratory of Immunology, Istituto Dermopatico  
dell'Immacolata, IRCCS, Rome, 00167, Italy  
SOURCE: Journal of Investigative Dermatology (2002), 118(6),  
1052-1058  
CODEN: JIDEAE; ISSN: 0022-202X  
PUBLISHER: Blackwell Publishing, Inc.  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Development of allergic contact dermatitis to haptens depends upon a  
balance between CD8+ T lymphocytes with pathogenic activity and CD4+ T  
cells, which comprise both effector and regulatory cells. Thus,  
differential recruitment of CD8+ and CD4+ lymphocytes to sites of hapten  
challenge may have considerable impact on disease expression. Here the  
migration of cutaneous lymphocyte-assocd. antigen+, nickel-specific CD8+  
and CD4+ T cell lines were compared with a panel of chemokines produced  
in the skin during allergic contact dermatitis. CCL17/TARC and CCL22/MDC  
induced a 3-fold higher migration of CD4+ compared with CD8+ lymphocytes.  
In contrast, CXCL10/IP-10 was 2-fold more potent in attracting CD8+  
cells.

These findings were consistent with the higher expression of CCR4  
and CXCR3 on CD4+ and CD8+ T cell lines, resp. Moreover, CCR4  
expression was high on nickel-specific T helper 2, intermediate on T  
helper 1 and T cytotoxic 2, and almost undetectable on T cytotoxic 1  
clones. On the contrary, CXCR3 was expressed by T cytotoxic 1 and 2 and

T helper 1, but not T helper 2 clones. Reverse transcription-polymerase  
chain reaction anal. of the skin before and after hapten challenge  
revealed the constitutive presence of TARC, and the early appearance of  
CCL2/MCP-1, followed by IP-10, CCL4/MIP-1.beta., and MDC mRNA.  
Supernatants from activated keratinocytes induced a strong migration of  
CD8+ lymphocytes, which was blocked by neutralization of IP-10.  
Conversely, supernatants from immature and mature dendritic cells  
attracted mostly CD4+ lymphocytes in a TARC- and MDC-dependent manner.  
Our data indicate that distinct chemokines and cell types control the  
accumulation of CD8+ and CD4+ T cells within inflamed skin.

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR  
THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L1 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:354656 CAPLUS  
DOCUMENT NUMBER: 137:31703  
TITLE: Cytokines and chemoattractants in allergic  
inflammation  
AUTHOR(S): Romagnani, S.  
CORPORATE SOURCE: Department of Internal Medicine, and Respiratory  
Diseases, Allergy, Section of Clinical Immunology,  
University of Florence, Florence, 50134, Italy  
SOURCE: Molecular Immunology (2002), 38(12-13), 881-885  
CODEN: MOIMD5; ISSN: 0161-5890  
PUBLISHER: Elsevier Science Ltd.  
DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. It is now generally accepted that type 2 T helper (Th2) cytokines and some chemoattractants play an essential role in the pathogenesis of the allergic inflammation. The effects of Th2 cytokines, such as interleukin (IL)-4, IL-5, IL-9, and IL-13, account for virtually all the pathophysiol. manifestations of **allergy** and asthma. Moreover, both Th2 cells and the effector cells usually present in the areas of allergic inflammation (basophils, mast cells, and eosinophils) express chemoattractant receptors, such as CCR3, **CCR4**, CCR8, and CRTH2. Therefore, interactions of eotaxin(s), eotaxin/CCL11,

RANTES/CCL5, and MCP-1/CCL2, MCP-2/CCL8, MCP-3/CCL7, MCP-4/CCL13 with CCR3 are responsible for the recruitment of basophils, eosinophils and mast cells, whereas interactions of **CCR4** with MDC/CCL22 or TARC/CCL17, CCR8 with I-309/CCL1, and CRTH2 with PGD2 play a crit. role in the allergen-induced recruitment of Th2 cells in the target tissues of allergic inflammation. The demonstration that Th2-polarized responses against allergens represent the triggering event for the development of allergic diseases, together with the recognition that some chemoattractants are responsible for the recruitment of both Th2 cells

and other effector cells of allergic inflammation, can provide the conceptual basis for the development of new therapeutic strategies in allergic conditions.

REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L1 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:304568 CAPLUS

DOCUMENT NUMBER: 137:167744

TITLE: The role of TARC in the pathogenesis of allergic asthma

AUTHOR(S): Berin, M. Cecilia

CORPORATE SOURCE: Division of Pediatric Allergy and Immunology, Mount Sinai School of Medicine, New York, NY, USA

SOURCE: Drug News & Perspectives (2002), 15(1), 10-16  
CODEN: DNPEED; ISSN: 0214-0934

PUBLISHER: Prous Science

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. TARC (thymus and activation-regulated chemokine), as a selective chemoattractant of Th2 cells, is a reasonable candidate as a key

regulator of Th2-mediated inflammation in allergic asthma. Studies have detd. that TARC is up-regulated in the airways of human subjects with asthma and that **CCR4**- and CCR8-bearing T cells are also present in the airways of asthmatic subjects after allergen challenge. Mouse models of allergic airway inflammation have shown that neutralization of TARC can not only inhibit T-cell and eosinophil infiltration into the

lung but can also inhibit bronchial hyperresponsiveness. The exact mechanism by which TARC can participate in allergic inflammation and what triggers the expression of TARC following allergen exposure is still unknown. Studies suggest that it could be involved not only in allergic asthma,

but

in the pathogenesis of allergic Th2-mediated diseases in general.

REFERENCE COUNT: 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L1 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2001:780964 CAPLUS  
 DOCUMENT NUMBER: 135:330487  
 TITLE: Uses of interleukin 174 agonists and antagonists  
 INVENTOR(S): Hurst, Stephen D.; Zurawski, Sandra M.; Rennick, Donna  
 PATENT ASSIGNEE(S): M.  
 SOURCE: Schering Corporation, USA  
 PCT Int. Appl., 29 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001079288	A2	20011025	WO 2001-US12493	20010417
WO 2001079288	A3	20020510		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-198488P P 20000418

AB Agonists or antagonists of the cytokine designated IL-174, and various methods of their use are provided. In particular, the methods make use of facts that many activities of the IL-174 cytokine are described. The agonists and antagonists may be used in therapy of many different types of diseases and infections.

L1 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2001:709559 CAPLUS  
 DOCUMENT NUMBER: 136:323434  
 TITLE: Chemoattractant Receptors Expressed on Type 2 T Cells and Their Role in Disease  
 AUTHOR(S): Cosmi, Lorenzo; Annunziato, Francesco; Maggi, Enrico; Romagnani, Sergio; Manetti, Roberto  
 CORPORATE SOURCE: Department of Internal Medicine, Section of Clinical Immunology, Allergy and Respiratory Diseases, University of Florence, Italy  
 SOURCE: International Archives of Allergy and Immunology (2001), 125(4), 273-279  
 CODEN: IAAIEG; ISSN: 1018-2438  
 PUBLISHER: S. Karger AG  
 DOCUMENT TYPE: Journal; General Review  
 LANGUAGE: English

AB A review. The existence of two functionally distinguished populations among T cells has been established in both mice and humans. Type 1 T helper (Th1) cells are involved in the defense against intracellular bacteria and many viruses, while type 2 Th cells (Th2) are the major

actors in the response against parasites and play a central role in allergic inflammation. More recently, several data have suggested that some chemokine receptors are tightly regulated on T cells, and in accordance with this selective expression, Th1 and Th2 cells can be differentially recruited by specific chemokines to the inflammatory sites.

Among Th2-associated chemokine receptors, CCR3, CCR4 and CCR8 have been described to play a central role in allergic inflammation. However, CCR3 is mainly expressed on basophils, eosinophils and mast cells, but it is poorly expressed by Th2 cells, and CCR4 is also expressed by Th subsets different from Th2 cells. So far, the chemoattractant receptors which among T cells appear to be selectively expressed by Th2 cells or their subsets are CCR8 and CRTH2. The ligand for CRTH2 is not a chemokine, but is prostaglandin (PG)D<sub>2</sub>, which is able to attract basophils, eosinophils, Th2 cells and type 2 cytotoxic (Tc2) CD8+ T lymphocytes. The selective expression of CRTH2 on Th2 and Tc2 cells may be useful to develop new therapeutic strategies against allergic diseases and against other immune disorders. Addnl. studies, however, are required

to understand its effective importance in the induction and maintenance of

Th2- or Tc2-mediated response and inflammation.

REFERENCE COUNT: 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L1 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:693651 CAPLUS

DOCUMENT NUMBER: 135:240908

TITLE: Assay for agents that induce chemokinesis

INVENTOR(S): Carson, Dennis A.; Leoni, Lorenzo M.; Cottam, Howard B.

PATENT ASSIGNEE(S): Regents of the University of California, USA

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001069240	A1	20010920	WO 2001-US8581	20010316
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

US 2002010125 A1 20020124 US 2001-810010 20010316

PRIORITY APPLN. INFO.: US 2000-189976P P 20000316

AB The present invention provides methods for identifying compds. that can induce cellular chemokinesis. According to the present invention, chemokinesis interferes with immune and inflammatory responses by increasing cell movements and altering cell migration patterns. Surprisingly, compds. isolated according to the present invention can

interfere with the spread of malignant cells through the body, reduce inflammatory responses and can cause leukocytes to be retained in lymph nodes, the spleen and other organs of the reticulo-endothelial system. Several methods are contemplated by the present invention for identifying compds. which can induce chemokinesis. In one embodiment the method involves contacting a population of target cells with a test compd. and observing whether the target cells produce a chemotactic mol.; wherein the target cell has a cognate receptor for the chemotactic mol. In another embodiment, the method involves contacting a population of target cells with a test compd. and observing whether the targets cells homotypically aggregate. In yet another embodiment, the method involves contacting a population of target cells with a test compd. and observing whether actin filaments in the target cells form stress fibers.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L1 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:402803 CAPLUS

DOCUMENT NUMBER: 136:84180

TITLE: Chemokines, chemokine receptors and **allergy**

AUTHOR(S): Kaplan, Allen P.

CORPORATE SOURCE: Division of Pulmonary Diseases and Central Case Medicine and Allergy and, Medical University of South Carolina, Charleston, SC, USA

SOURCE: International Archives of Allergy and Immunology (2001), 124(4), 423-431

CODEN: IAAIEG; ISSN: 1018-2438

PUBLISHER: S. Karger AG

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Chemokines are a group of cytokines that are responsible for the influx of blood cells, including T and B lymphocytes, monocytes, neutrophils, eosinophils and basophils, in allergic and other

inflammatory conditions. They function as G protein-coupled chemotactic factors which also activate the cells with which they interact. Certain chemokines function within the afferent arm of the immune system, in which antigen

is processed and antibody formation initiated, and others are active within the effector pathways of cellular immunity and late-phase allergic reactions. Th2 lymphocytes, which are crit. for **allergy**, employ the CC chemokine receptors **CCR4** and **CCR8** with the ligands thymus- and activation-regulated chemokine (TARC), macrophage-derived chemokine (MDC) and I-309, resp. The chemokine receptor **CCR3** and ligands monocyte chemoattractant protein (MCP)-3, MCP-4, regulated upon

activation normal T cell expressed and secreted (RANTES) and eotaxins I and II are of

particular relevance for the recruitment and activation of eosinophils. Th1 reactions depend upon interferon .gamma.-induced CXC chemokines interferon-inducible protein (IP)-10, interferon-inducible T cell-.alpha. chemoattractant (iTAC) and monokine induced by interferon-.gamma. (MiG), which bind to chemokine receptor CXCR3.

REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT



L1 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:340634 CAPLUS  
DOCUMENT NUMBER: 135:70896  
TITLE: Inhibition of **CCR4** ligands production by  
oriental medicines  
AUTHOR(S): Hirai, Koichi; Nakajima, Toshiharu; Cyong, Jong Chol  
CORPORATE SOURCE: Dep. Bioregul. Funct., Univ. Tokyo, Grad. Sch. Med.,  
Tokyo, Japan  
SOURCE: Kanpo to Men'eki, Arerugi (2000), 14, 121-129  
CODEN: KMARED; ISSN: 0914-6407  
PUBLISHER: Fama Intanashionaru  
DOCUMENT TYPE: Journal  
LANGUAGE: Japanese

AB Allergic inflammation is a Th2-dominant immune reaction. Thymus- and  
activation-regulated chemokine (TARC) is a ligand specific to the  
receptor

**CCR4**, which is preferentially expressed Th2, there by being  
supposed to participate in the development of allergic inflammation.

TARC  
derived from respiratory epithelial cells play a closely connected part  
in  
the pathogenesis of airway **allergy** through chemoattraction of  
Th2 cells. This study uses respiratory epithelial cells to investigate  
the effect of oriental medical prepns. on TARC prodn. Large quantities  
(ng/mL order) of TARC were produced in the supernatant of cultures of

A549  
human respiratory epithelial cells co-stimulated by TNF-.alpha. and IL-4.  
Thirteen oriental prepns., including Ogon (Huang-Qin) and Oren  
(Huang-Lian), were shown to inhibit TARC prodn., with Mao (Ma-Huang)  
demonstrating esp. strong inhibition action. It inhibited accumulation  
of

TARC mRNA indicating that Mao inhibits TARC prodn. at the level of  
transcription. Ephedrine and pseudoephedrine, major components of Mao,  
also inhibited TARC prodn. at the protein and mRNA levels.

L1 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:300895 CAPLUS  
DOCUMENT NUMBER: 134:279681  
TITLE: Process for producing polypeptide  
INVENTOR(S): Ogawa, Tatsuya; Konno, Yoshinobu; Akashi, Naohisa;  
Takasugi, Hiroshi; Sugimoto, Seiji; Yano, Keiichi  
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 41 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001029246	A1	20010426	WO 2000-JP7288	20001019
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,			

CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2000079504	A5 20010430	AU 2000-79504	20001019
EP 1229125	A1 20020807	EP 2000-969908	20001019

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL

PRIORITY APPLN. INFO.: JP 1999-296267 A 19991019  
WO 2000-JP7288 W 20001019

AB A process for producing a desired polypeptide by using rat cells. More particularly speaking, a process for producing the polypeptide which comprises culturing rat cells such as YB2/3HL.P2.G11.16Ag.20 (hereinafter referred to as YB2/0), preferably rat cells obtained by transferring a recombinant DNA contg. a DNA encoding the desired polypeptide such as an immunol. functional mol., in a serum-free medium. Among the desired polypeptides obtained by this method, an antibody obtained by, for example, using transformants of YB2/0 has a high antibody-dependent cytotoxic activity and thus is useful as drugs.

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L1 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:125162 CAPLUS

DOCUMENT NUMBER: 134:294296

TITLE: T cell phenotypes of the normal nasal mucosa:  
induction of Th2 cytokines and CCR3 expression by  
IL-4

AUTHOR(S): Till, Stephen J.; Jopling, Louise A.; Wachholz, Petra  
A.; Robson, Rachel L.; Qin, Shixin; Andrew, David P.;  
Wu, Lijun; Van Neerven, Joost; Williams, Timothy J.;  
Durham, Stephen R.; Sabroe, Ian

CORPORATE SOURCE: Upper Respiratory Medicine, National Heart and Lung  
Institute Division, Biomedical Sciences Division,  
Imperial College School of Medicine, London, UK

SOURCE: Journal of Immunology (2001), 166(4), 2303-2310  
CODEN: JOIMA3; ISSN: 0022-1767

PUBLISHER: American Association of Immunologists

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Mucosal environments such as that of the nose are points of first contact  
between the human organism and its environment. At these sites the  
immune  
system must be regulated to differentiate between and respond  
appropriately to pathogens and harmless contaminants. T cell-driven  
immune responses broadly fall into Th1- or Th2-type phenotypes, with  
increasing evidence that the recruitment of these T lymphocyte subsets is  
mediated by selective expression of specific chemokine receptors. We  
have  
investigated the immunol. of the normal nasal mucosa. We show that nasal  
T cell lines from normal individuals, expanded by culture in IL-2, show  
reduced expression of the Th2-type cytokines IL-4 and IL-5 compared with  
lines derived from the blood of the same subjects. These T cells also  
show reduced expression of the Th2-selective chemokine receptor, CCR3,  
but  
similar levels of CCR4 compared with the blood-derived lines.  
This apparent suppression of Th2 cytokine and CCR3 expression by nasal T  
cells was reversed by addn. of IL-4 to the culture medium. These data  
are  
consistent with the presence of a nasal mucosal microenvironment that  
suppresses Th2 responses and may represent a protective measure against

atopic allergic disease in humans and a favoring of Th1 responses to infectious agents. In contrast, T cell expression of CCR1 was higher in the nose than in the blood regardless of the culture medium cytokine environment in keeping with a role for this receptor in tissue homing or lymphocyte activation.

REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L1 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:122695 CAPLUS

DOCUMENT NUMBER: 135:225348

TITLE: Chemokines and allergic diseases

AUTHOR(S): Adachi, Yuichi; Yamamoto, Junko; Miyawaki, Toshio

CORPORATE SOURCE: School of Medicine, Department of Pediatrics, Toyama Medical and Pharmaceutical University, Japan

SOURCE: Molecular Medicine (Tokyo) (2001), 38(2), 160-166  
CODEN: MOLMEL; ISSN: 0918-6557

PUBLISHER: Nakayama Shoten

DOCUMENT TYPE: Journal; General Review

LANGUAGE: Japanese

AB A review with 26 refs. on the role of eotaxin-CCR3 chemokines in the aggregation of inflammatory cells in **allergies**, chemokines in **allergies**, and the movement of T cell subsets (CCR4-pos. T cells, Th1 cells, Th2 cells) in **allergies**.

L1 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:100131 CAPLUS

DOCUMENT NUMBER: 134:251122

TITLE: Intervention of thymus and activation-regulated chemokine attenuates the development of allergic airway inflammation and hyperresponsiveness in mice

AUTHOR(S): Kawasaki, Shin; Takizawa, Hajime; Yoneyama, Hiroyuki; Nakayama, Takashi; Fujisawa, Ryuichi; Izumizaki, Masahiko; Imai, Toshio; Yoshie, Osamu; Homma, Ikuo; Yamamoto, Kazuhiko; Matsushima, Kouji

CORPORATE SOURCE: Department of Respiratory Medicine, Molecular Preventive Medicine, School of Medicine, University

of Tokyo, Tokyo, Japan

SOURCE: Journal of Immunology (2001), 166(3), 2055-2062  
CODEN: JOIMA3; ISSN: 0022-1767

PUBLISHER: American Association of Immunologists

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Thymus- and activation-regulated chemokine (TARC; CCL17) is a lymphocyte-directed CC chemokine that specifically chemoattracts CC chemokine receptor 4-pos. (CCR4+) Th2 cells. To establish the pathophysiol. roles of TARC in vivo, we investigated here whether an mAb against TARC could inhibit the induction of asthmatic reaction in mice elicited by OVA. TARC was constitutively expressed in the lung and was up-regulated in allergic inflammation. The specific Ab against TARC attenuated OVA-induced airway eosinophilia and diminished the degree of airway hyperresponsiveness with a concomitant decrease in Th2 cytokine levels. Our results for the first time indicate that TARC is a pivotal chemokine for the development of Th2-dominated exptl. allergen-induced asthma with eosinophilia and AHR. This study also represents the first success in controlling Th2 cytokine prodn. in vivo by targeting a chemokine.

REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR  
THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L1 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2000:903436 CAPLUS  
DOCUMENT NUMBER: 135:120758  
TITLE: Non-redundant functional groups of chemokines operate  
in a coordinate manner during the inflammatory  
response in the lung  
AUTHOR(S): Gutierrez-Ramos, J. -C.; Lloyd, C.; Kapsenberg, M.  
L.;  
Gonzalo, J. A.; Coyle, A. J.  
CORPORATE SOURCE: Millennium Pharmaceuticals Inc, Cambridge, MA, 02139,  
USA  
SOURCE: Immunological Reviews (2000), 177, 31-42  
CODEN: IMRED2; ISSN: 0105-2896  
PUBLISHER: Munksgaard International Publishers Ltd.  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English

AB A review with 66 refs. The understanding of the relative contribution of  
particular chemokines to the selective accumulation of leukocyte subsets  
to an organ site during an inflammatory response is made difficult by the  
simultaneous presence of multiple chemokines with partially overlapping  
functions at the inflammatory site. The study of several chemokine  
pathways (expression and function) during the development of a mouse  
model  
of allergic airway disease (AAD) has revealed differential expression  
regulation with distinct cellular sources for individual chemokines with  
functional bias for the recruitment/localization of regulatory and/or  
effector leukocyte subsets. In the present review, we propose that  
distinct functional groups of chemokines cooperate to generate the  
complete inflammatory response in the lung during AAD. We will also  
extend these concepts to the specific recruitment of a key cellular  
subset  
such as T helper type 2 (Th2) lymphocytes. We propose that the long term  
recruitment of antigen-specific Th2 cells to target organs, such as  
airways during chronic lung inflammation, is the result the sequential  
involvement of several chemotactic axes. Specifically, the CCR3/eotaxin  
and the **CCR4**/MDC pathway act in a coordinated cooperative  
manner, with the CCR3/eotaxin pathway being crit. in the acute/early  
stages of a response, followed by the **CCR4**/MDC pathway, which  
ultimately dominates in the recruitment of antigen-specific Th2 cells.  
Other chemokines/receptors participate in this process possibly by  
amplifying/priming the Th2 recruitment response.

REFERENCE COUNT: 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR  
THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L1 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2000:756484 CAPLUS  
DOCUMENT NUMBER: 133:329593  
TITLE: Low adenosine anti-sense oligonucleotide,  
compositions, kit and method for treatment of airway  
disorders associated with bronchoconstriction, lung  
inflammation, **allergy**(ies) and surfactant  
depletion  
INVENTOR(S): Nyce, Jonathan W.

PATENT ASSIGNEE(S): East Carolina University, USA  
 SOURCE: PCT Int. Appl., 1592 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000062736	A2	20001026	WO 2000-US8020	20000324
WO 2000062736	A3	20011011		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

BR 2000006019	A	20010313	BR 2000-6019	20000324
EP 1168919	A2	20020109	EP 2000-919668	20000324

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.: US 1999-127958P P 19990406  
 WO 2000-US8020 W 20000324

OTHER SOURCE(S): MARPAT 133:329593

AB An in vivo method of selectively delivering a nucleic acid to a target gene or mRNA, comprises the topical administration, e.g. to the respiratory system, of a subject of a therapeutic amt. of an oligonucleotide (oligo) that is antisense to the initiation codon region, the coding region, the 5' or 3' intron-exon junctions or regions within 2 to 10 nucleotides of the junctions of the gene or antisense to a mRNA complementary to the gene in an amt. effective to reach the target polynucleotide and reducing or inhibiting expression. In addn. a method of treating an adenosine-mediated effect comprises topically

administering

to a subject an antisense oligo in an amt. effective to treat the respiratory, pulmonary, or airway disease. In order to minimize triggering adenosine receptors by their metab., the administered oligos have a low content of or are essentially free of adenosine. A pharmaceutical compn. and formulations comprise the oligo antisense to an adenosine receptor, genes and mRNAs encoding them, genomic and mRNA flanking regions, intron and exon borders and all regulatory and functionally related segments of the genes and mRNAs encoding the polypeptides, their salts and mixts. Various formulations contain a requisite carrier, and optionally other additives and biol. active

agents.

The low-adenosine or adenosine-free (des-A) agent for practicing the method of the invention may be prepd. by selecting a target gene(s), genomic flanking region(s), RNA(s) and/or polypeptide(s) assocd. with a disease(s) or condition(s) afflicting lung airways, obtaining the

sequence

of the mRNA(s) corresponding to the target gene(s) and/or genomic

flanking

region(s), and/or RNAs encoding the target polypeptide(s), selecting at least one segment of the mRNA which may be up to 60 % free of thymidine (T) and synthesizing one or more anti-sense oligonucleotide(s) to the

mRNA

segments which are free of adenosine (A) by substituting a universal base for A when present in the oligonucleotide. The agent may be prepd. by selection of target nucleic acid sequences with GC running stretches, which have low T content, and by optionally replacing A in the antisense oligonucleotides with a "Universal or alternative base". The agent, compn. and formulations are used for prophylactic, preventive and therapeutic treatment of ailments assocd. with impaired respiration, lung **allergy**(ies) and/or inflammation and depletion lung surfactant or surfactant hypoprodn., such as pulmonary vasoconstriction, inflammation, **allergies**, allergic rhinitis, asthma, impeded respiration, lung pain, cystic fibrosis, bronchoconstriction. The present treatment is suitable for administration in combination with other treatments, e.g. before, during and after other treatments, including radiation, chemotherapy, antibody therapy and surgery, among others. Alternatively, the present agent is effectively administered prophylactically or therapeutically by itself for conditions without known therapies or as a substitute for therapies exhibiting undesirable side effects. The treatment of this invention may be administered directly into the respiratory system of a subject so that the agent has direct access to the lungs, or by other effective routes of administration, e.g. topically, transdermally, by implantation, etc., in an amt. effective to reduce or inhibit the symptoms of the ailment.

L1 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2000:628006 CAPLUS  
 DOCUMENT NUMBER: 133:217723  
 TITLE: Method for validating/invalidating target(s) and pathways  
 INVENTOR(S): Nyce, Jonathan W.  
 PATENT ASSIGNEE(S): Epigenesis Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 53 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000051621	A1	20000908	WO 2000-US5643	20000302
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000009247	A	20011120	BR 2000-9247	20000302
EP 1165093	A1	20020102	EP 2000-913730	20000302
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002537792	T2	20021112	JP 2000-602288	20000302
PRIORITY APPLN. INFO.:			US 1999-122950P	P 19990305
			WO 2000-US5643	W 20000302
OTHER SOURCE(S): MARPAT 133:217723				
AB A method of detg. the existence of a correlation between a function of a disease or condition and a gene or mRNA encoding a target polypeptide				

suspected of being assocd. with a disease or condition, comprises obtaining oligonucleotides (oligos) consisting of up to about 15 % adenosine (A), preferably having no adenosine content, and which is anti-sense to a target selected from the group consisting of target genes and their corresponding mRNAs, genomic and mRNA flanking regions selected from the group consisting of 3' and 5' intron-exon borders and the juxta-section between coding and non-coding regions, and all mRNA segments

encoding polypeptides assocd. with a pre-selected disease or condition; selecting amongst the oligos one that significantly inhibits or ablates expression of the polypeptide encoded by the mRNA upon in vitro hybridization to the target mRNA; administering to a subject an amt. of the selected oligo effective for in vivo hybridization to the target

mRNA; and assessing a subject's function that is assocd. with the disease or condition before and after administration of the oligo; wherein a change in the function's value greater than about 70% indicates a pos. correlation, between about 40 and about 70% a possible correlation, and below about 30% a lack of correlation. The present method preferably administers the oligos in situ where the target is located, e.g. into the subject's respiration when validating targets assocd. with malignant and other pulmonary and respiratory functions, so that the agent has direct access to the lungs. Alternatively, such desAdenosine oligos may be delivered directly to the CNS or other organs, tissues and organ systems, by known delivery formulations. This invention provides a rapid,

reliable method for drug target validation/invalidation in various biol. systems that utilize proprietary low or desAdenosine antisense oligonucleotides. Using desAdenosine antisense oligonucleotides, the present method may validate/invalidate potential gene targets with a level of speed and accuracy that has heretofore been impossible using traditional techniques.

The use of antisense oligonucleotides to target adenosine receptors is described. Adenosine A1 receptor antisense oligonucleotides had bronchodilator activity in rabbits and adenosine A3 receptor antisense oligonucleotides had anti-inflammatory activity in asthmatic rabbits.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L1 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:223049 CAPLUS

DOCUMENT NUMBER: 130:251233

TITLE: Macrophage-derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and their therapeutic applications

INVENTOR(S): Gray, Patrick W.; Chantry, David H.; Deeley, Michael C.; Raport, Carol J.; Godiska, Ronald

PATENT ASSIGNEE(S): Icos Corporation, USA

SOURCE: PCT Int. Appl., 159 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9915666	A2	19990401	WO 1998-US20270	19980928
WO 9915666	A3	19990916		

SOURCE: International Archives of Allergy and Immunology  
(2001), 124(4), 423-431  
CODEN: IAAIEG; ISSN: 1018-2438  
PUBLISHER: S. Karger AG  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English

AB A review. Chemokines are a group of cytokines that are responsible for the influx of blood cells, including T and B lymphocytes, monocytes, neutrophils, eosinophils and basophils, in allergic and other inflammatory conditions. They function as G protein-coupled chemotactic factors which also activate the cells with which they interact. Certain chemokines function within the afferent arm of the immune system, in which antigen is processed and antibody formation initiated, and others are active within the effector pathways of cellular immunity and late-phase allergic reactions. Th2 lymphocytes, which are crit. for **allergy**, employ the CC chemokine receptors CCR4 and CCR8 with the ligands thymus- and activation-regulated chemokine (TARC), macrophage-derived chemokine (MDC) and I-309, resp. The chemokine receptor CCR3 and ligands monocyte chemoattractant protein (MCP)-3, MCP-4, regulated upon activation of normal T cell expressed and secreted (RANTES) and eotaxins I and II are of particular relevance for the recruitment and activation of eosinophils. Th1 reactions depend upon interferon .gamma.-induced CXC chemokines interferon-inducible protein (IP)-10, interferon-inducible T cell-.alpha. chemoattractant (iTAC) and monokine induced by interferon-.gamma. (MiG), which bind to chemokine receptor CXCR3.

REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L2 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:296102 CAPLUS

DOCUMENT NUMBER: 135:75647

TITLE: Stem cell factor and IgE-stimulated murine mast cells produce chemokines (CCL2, CCL17, CCL22) and express chemokine receptors

AUTHOR(S): Oliveira, S. H. P.; Lukacs, N. W.

CORPORATE SOURCE: University of Michigan Medical School - Department of Pathology, Ann Arbor, MI, 48109-0602, USA

SOURCE: Inflammation Research (2001), 50(3), 168-174  
CODEN: INREFB; ISSN: 1023-3830

PUBLISHER: Birkhaeuser Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Objective and design: In the present study we investigated the effect of SCF and/or IgE on histamine, TNF-.alpha. and chemokines released from bone marrow-derived mast cells (BMMC) as well as chemokine receptor expression.

Material and methods: BMMC were derived from femoral bone marrow of CBA/J mice. The purity of BMMC was >98% after 3 wk. BMMC (2.5 .times. 10<sup>6</sup> cells/well) were incubated in the presence or absence of either SCF, IgE plus DNP or a combination of SCF and IgE for 6 and 18 h. Cell-free supernatants were recovered to measure CC chemokines, TNF-.alpha. and histamine release utilizing ELISA assays. CC chemokine family receptors were detected by RT-PCR anal., and confirmed using functional chemotactic



assays. Results: Histamine levels were comparable between SCF and IgE stimulated cells, whereas TNF-.alpha. prodn. was significantly greater after IgE compared to SCF stimulation. SCF and/or IgE-stimulated BMMC released CC chemokines, CCL22 (MDC), CCL17 (TARC) and CCL2 (MCP-1). Increased mRNA expression of CCR1, CCR2, CCR3, and CCR5 was detected in SCF and IgE-stimulated BMBCs. Functional chemotactic assays confirmed the expression data. Conclusion: SCF and IgE can up-regulate the expression of chemokines and chemokine receptors on mast cells.

Thus,

SCF may play a significant role in their activation and inflammation during allergic responses.

REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L2 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:903436 CAPLUS

DOCUMENT NUMBER: 135:120758

TITLE: Non-redundant functional groups of chemokines operate in a coordinate manner during the inflammatory response in the lung

AUTHOR(S): Gutierrez-Ramos, J. -C.; Lloyd, C.; Kapsenberg, M. L.;

CORPORATE SOURCE: Gonzalo, J. A.; Coyle, A. J. Millennium Pharmaceuticals Inc, Cambridge, MA, 02139, USA

SOURCE: Immunological Reviews (2000), 177, 31-42  
CODEN: IMRED2; ISSN: 0105-2896

PUBLISHER: Munksgaard International Publishers Ltd.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review with 66 refs. The understanding of the relative contribution of particular chemokines to the selective accumulation of leukocyte subsets to an organ site during an inflammatory response is made difficult by the simultaneous presence of multiple chemokines with partially overlapping functions at the inflammatory site. The study of several chemokine pathways (expression and function) during the development of a mouse model

of allergic airway disease (AAD) has revealed differential expression regulation with distinct cellular sources for individual chemokines with functional bias for the recruitment/localization of regulatory and/or effector leukocyte subsets. In the present review, we propose that distinct functional groups of chemokines cooperate to generate the complete inflammatory response in the lung during AAD. We will also extend these concepts to the specific recruitment of a key cellular subset

such as T helper type 2 (Th2) lymphocytes. We propose that the long term recruitment of antigen-specific Th2 cells to target organs, such as airways during chronic lung inflammation, is the result the sequential involvement of several chemotactic axes. Specifically, the CCR3/eotaxin and the CCR4/MDC pathway act in a coordinated cooperative manner, with the CCR3/eotaxin pathway being crit. in the acute/early stages of a response, followed by the CCR4/MDC pathway, which ultimately dominates in the recruitment of antigen-specific Th2 cells. Other chemokines/receptors participate in this process possibly by amplifying/priming the Th2 recruitment response.

REFERENCE COUNT: 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L2 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:68155 CAPLUS  
DOCUMENT NUMBER: 132:106969  
TITLE: Chemokines as adjuvants of immune response  
INVENTOR(S): Caux, Christophe; Vanbervliet, Beatrice; Lebecque, Serge; Vicari, Alain; Dieu, Marie-Caroline  
PATENT ASSIGNEE(S): Schering-Plough, Fr.  
SOURCE: Eur. Pat. Appl., 16 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 974357	A1	20000126	EP 1998-401799	19980716
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
WO 2000003728	A1	20000127	WO 1999-US14148	19990715
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9949591	A1	20000207	AU 1999-49591	19990715
US 2002034494	A1	20020321	US 2001-768917	20010124
WO 2002058723	A2	20020801	WO 2002-US1849	20020122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: EP 1998-401799 A 19980716  
WO 1999-US14148 W 19990715  
US 2001-768917 A 20010124

AB Dendritic cells play a crit. role in antigen-specific immune responses. Materials and methods are provided for treating disease states, including cancer and autoimmune disease, by facilitating or inhibiting the migration

or activation of antigen-presenting dendritic cells. In particular, chemokines are used to initiate, amplify or modulate an immune response. In one embodiment, chemokines are used to attract dendritic cells to the site of antigen delivery. An increase no. of dendritic at the site of antigen delivery means more antigen uptake and a modified immune response.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L2 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:796268 CAPLUS